• Clinical Instructor, Global Health
  • Assistant Deputy Chief, Communicable Diseases, Public Health - Seattle & King County

Bill & Melinda Gates Foundation
500 Fifth Avenue North
Seattle, WA 98109
United States

Phone Number: 
206-770-1913
Fax: 
Select from the following:
Biography 

Matt Hanson, MD, DTM&H is a public health physician, with areas of focus including measles and rubella elimination efforts, routine immunization strengthening, and public health system strengthening. He has previously worked at the Bill & Melinda Gates Foundation, the Centers for Disease Control and Prevention, and the World Health Organization.

Matt received a Diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine. He underwent residency training in Internal Medicine at the University of California, San Francisco and received his B.S. and M.D. degrees from the University of Washington.

Education 
  • DTM&H (London School of Hygiene & Tropical Medicine (UK))
  • MD (University of Washington)
  • BS (University of Washington)
Country Affiliations 
Health Topics 
  • COVID-19
  • Disease Surveillance
  • Epidemiology
  • Immunizations
  • Infectious Diseases (other than STDs)
DGH Centers, Programs and Initiatives and Affiliated Organizations 
Expertise 

Immunization

Publications 

COVID-19 Outbreak Among Three Affiliated Homeless Service Sites — King County, Washington, 2020. MMWR 2020 May 1;69(17);523–526.

Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters — Four U.S. Cities, March 27–April 15, 2020. MMWR 2020 May 1;69(17);521–522.

Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications. Vaccine 2020 Jan 29;38(5):979-992.

Accelerating measles and rubella elimination through research and innovation – Findings from the measles & rubella initiative research prioritization process, 2016. Vaccine 2019 Sep 10;37(38):5754-5761.

Research priorities for accelerating progress toward measles and rubella elimination identified by a cross-sectional web-based survey. Vaccine 2019 Sep 10;37(38):5745-5753.